Onyx begins Phase I trials of Onyx-015 adenovirus for p53-deficient tumors -- IPO prospectus.
ONYX COMMENCES PHASE I TRIALS OF ONYX-015 FOR p53-DEFICIENT TUMORS, the company discloses in its initial public offering prospectus. Trials of the genetically engineered adenovirus began in the U.S. and U.K. in April and will enroll patients with p53-deficient tumors of the head and neck. Preclinical development is ongoing in p53-deficient ovarian, liver and other cancers.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth